Patents Represented by Attorney, Agent or Law Firm Soma G. Simon
  • Mmuscarinic acetylcholine receptor antagonists
    Patent number: 7232841
    Abstract: Novel thiazole aniline compounds, pharmaceutical compositions, methods of making them and uses thereof in treating M3 muscarinic acetylcholine receptor mediated diseases are disclosed.
    Type: Grant
    Filed: April 7, 2004
    Date of Patent: June 19, 2007
    Assignee: Glaxo Group Limited
    Inventors: Jakob Busch-Petersen, Dramane I. Laine, Michael R. Palovich, Brent W. McCleland
  • Calcilytic compounds
    Patent number: 7109238
    Abstract: Novel calcilytic compounds and methods of using them are provided.
    Type: Grant
    Filed: January 21, 2004
    Date of Patent: September 19, 2006
    Assignees: Smith Kline Beecham Corporation, NPS Pharmaceuticals, Inc.
    Inventors: Maria Amparo Lago, James Francis Callahan, Pradip Kumar Bhatnagar, Eric G. Del Mar, William M. Bryan, Joelle L. Burgess
  • IL-8 receptor antagonists
    Patent number: 7008962
    Abstract: This invention relates to the novel use of dianilino squarates in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
    Type: Grant
    Filed: May 30, 2001
    Date of Patent: March 7, 2006
    Assignee: Smithkline Beecham Corporation
    Inventors: Michael R. Palovich, Brent McCleland, Guangping Bi, Michelle Werner, Katherine L. Widdowson
  • Process for the preparation of an indole derivative
    Patent number: 6946565
    Abstract: A process for the preparation of methyl 2-(3-chloropropoxy)-indole-3-carboxylate, which comprises reacting a 3-chloro-3-carboxylate indole compound with 3-chloropropanol in the presence of an acid having a pKa of from 0 to 2.
    Type: Grant
    Filed: January 30, 2003
    Date of Patent: September 20, 2005
    Assignee: SmithKline Beecham PLC
    Inventors: Michael Fedouloff, John Bryce Strachan
  • Heterocyclic ureas, their preparation and their use as vanilloid receptor antagonists
    Patent number: 6939891
    Abstract: The invention relates to certain novel compounds having Vanilloid Receptor (VR1) antagonist activity, processes for their preparation, to compositions containing them and to their use in the treatment of various disorders.
    Type: Grant
    Filed: May 2, 2002
    Date of Patent: September 6, 2005
    Assignee: SmithKline Beecham, PLC
    Inventors: Harshad Kantilal Rami, Mervyn Thompson, Paul Adrian Wyman
  • Peptide deformylase inhibitors
    Patent number: 6897233
    Abstract: PDF inhibitors and novel methods for their use are provided.
    Type: Grant
    Filed: March 1, 2002
    Date of Patent: May 24, 2005
    Assignee: SmithKline Beecham Corporation
    Inventors: Jia-Ning Xiang, Siegfried B. Christensen, IV, Xiangmin Liao, Maxwell D. Cummings
  • Calcilytic compounds
    Patent number: 6864267
    Abstract: Novel calcilytic compounds and methods of using them are provided.
    Type: Grant
    Filed: July 16, 2001
    Date of Patent: March 8, 2005
    Assignee: SmithKline Beecham Corporation
    Inventors: Pradip K. Bhatnagar, James F. Callahan, Amparo M. Lago
  • Peptide deformylase inhibitors
    Patent number: 6852882
    Abstract: Novel PDF inhibitors and novel methods for their use are provided.
    Type: Grant
    Filed: June 4, 2002
    Date of Patent: February 8, 2005
    Assignee: SmithKline Beecham Corporation
    Inventors: Siegfried B. Christensen, IV, Maxwell D. Cummings, Joseph M. Karpinski
  • Peptide deformylase inhibitors
    Patent number: 6806369
    Abstract: PDF inhibitors and novel methods for their use are provided.
    Type: Grant
    Filed: November 5, 2002
    Date of Patent: October 19, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Kelly M. Aubart, Siegfried B. Christensen, IV, Jacques Briand, Maxwell David Cummings
  • Method for quantitative determination of amino acids
    Patent number: 6800486
    Abstract: A novel method for the determination of amino acids by HPLC using pre-column derivatization is described. In this procedure, the aminno acids are derivatized with 2-chlorobenzoxazole to yield highly fluroresent N-(2-benzoxazolyl)-amino acids (BOX-AAs) for detection at very high sensitivity. Derivatives can also be detected using conventional UV detection methods. The BOX-AAs can be separated on a C18 reversed phase column for quantitative estimation. This method can be used for the preparation of N-(2-benzoxazolyl)-amino acids in large amounts.
    Type: Grant
    Filed: June 7, 2001
    Date of Patent: October 5, 2004
    Assignee: SmithKline Beecham Corporation
    Inventor: Kalyan R Anumula
  • Peptide deformylase inhibitors
    Patent number: 6797730
    Abstract: Novel PDF inhibitors and novel methods for their use are provided.
    Type: Grant
    Filed: February 18, 2004
    Date of Patent: September 28, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Jia-Ning Xiang, Siegfried B. Christensen, IV, Jinhwa Lee
  • IL-8 receptor antagonists
    Patent number: 6767922
    Abstract: This invention relates to novel compounds of Formula (I) to (VII), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
    Type: Grant
    Filed: September 6, 2002
    Date of Patent: July 27, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Katherine Louisa Widdowson, Qi Jin
  • Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases
    Patent number: 6750195
    Abstract: A compound which acts as an antagonist at 5-HT4 receptors is of potential use in the treatment of conditions associated with bladder hypersensitivity, such as urinary incontinence, which is often associated with irritable bowel syndrome (IBS) and a compound which acts as an agonist at 5-HT4 receptors is of potential use in the treatment of conditions associated with a poorly functioning bladder, such as urinary bladder hypoactivity following prostectomy.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: June 15, 2004
    Assignee: SmithKline Beecham Corporation p.l.c.
    Inventors: Gareth John Sanger, Kay Alison Wardle
  • Fatty acid synthase inhibitors
    Patent number: 6723749
    Abstract: This invention relates to the use of compounds as inhibitors of the fatty acid synthase FabH.
    Type: Grant
    Filed: January 31, 2003
    Date of Patent: April 20, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Siegfried B. Christensen, Daniel J. Mercer, Jia-Ning Xiang
  • Morphinoid compounds
    Patent number: 6696457
    Abstract: Heterocycle condensed morphinoid derivatives of formula (I) have therapeutic utility as analgesics, in collagen disease, as anti-allergic and anti-inflammatory agents, brain cell protectants, in gastritis, diarrhoea, cardiovascular and respiratory diseases, cough, mental illness, epilepsy, for the preservation of organs during transplant operations, and for the treatment of those pathological conditions which customarily can be treated with agonists of the delta opioid receptor.
    Type: Grant
    Filed: April 2, 2002
    Date of Patent: February 24, 2004
    Assignees: SmithKline Beecham p.l.c., SmithKline Beecham S.p.A.
    Inventors: Stephen Edward Clarke, Giulio Dondio, Luca Francesco Raveglia, Silvano Ronzoni
  • IL-8 receptor antagonists
    Patent number: 6680317
    Abstract: This invention relates to novel compounds of Formula (I), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
    Type: Grant
    Filed: September 17, 2002
    Date of Patent: January 20, 2004
    Assignee: SmithKline Beecham Corporation
    Inventors: Michael R. Palovich, Katherine L. Widdowson, Hong Nie
  • Hydroxamic acid derivative as inhibitor of the formation of soluble human CD23
    Patent number: 6673965
    Abstract: A compound of formula (I) wherein: R isopropyl; n is 0; R1 is naphthylmethyl; R2 is t-butyl; and R3 is methyl; is useful in the treatment of disorders mediated by s-CD23.
    Type: Grant
    Filed: July 16, 2002
    Date of Patent: January 6, 2004
    Assignee: SmithKline Beecham P.L.C.
    Inventors: John Gerard Ward, Andrew Faller
  • Fatty acid synthase inhibitors
    Patent number: 6670388
    Abstract: This invention relates to the use of compounds as inhibitors of the fatty acid synthase FabH.
    Type: Grant
    Filed: December 13, 2002
    Date of Patent: December 30, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: Robert A. Daines, Siegfired B. Christensen, IV, Jack D. Leber, Martha S. Head
  • Il-8 receptor antagonists
    Patent number: 6664259
    Abstract: This invention relates to novel compounds of Formula (I) to (VII), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
    Type: Grant
    Filed: September 6, 2002
    Date of Patent: December 16, 2003
    Assignee: SmithKline Beecham Corporation
    Inventors: Katherine Louisa Widdowson, Qi Jin
  • Sulfonamide derivatives as 5-HT7 receptor antagonists
    Patent number: 6660751
    Abstract: The invention relates to novel sulfonamide compounds having 5-HT7 receptor antagonist activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.
    Type: Grant
    Filed: September 20, 2001
    Date of Patent: December 9, 2003
    Assignee: SmithKline Beecham p.l.c.
    Inventor: Peter John Lovell